Odyssey Therapeutics reports TNFR2 agonism reduces autoimmune inflammation in preclinical study
ODTX•Odyssey Therapeutics said published preclinical findings showed TNFR2 agonism reduced autoimmune disease severity in mice and promoted stable, tissue-directed regulatory T cells. The company expects its investigational TNFR2 agonist OD-003 to complete IND-enabling studies in the first quarter of 2027.
1. Preclinical findings
Odyssey Therapeutics announced published preclinical findings supporting TNFR2 agonism for autoimmune and inflammatory diseases. Treatment reduced disease severity in mice while promoting stable, tissue-directed regulatory T cells, and experiments with human cells supported similar effects.
2. OD-003 timeline
The tissue-directed differentiation observed in mice was not seen with an IL-2 mutein. Odyssey expects its investigational TNFR2 agonist OD-003 to complete IND-enabling studies in the first quarter of 2027.
